Search

PTC Therapeutics Inc

Gesloten

SectorGezondheidszorg

65.31 -5.24

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

66.72

Max

69.45

Belangrijke statistieken

By Trading Economics

Inkomsten

-135M

-52M

Verkoop

-2.7M

358M

K/W

Sectorgemiddelde

7.597

51.78

EPS

0.61

Winstmarge

-14.447

Werknemers

991

EBITDA

-140M

22M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+46.8% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-11M

5.1B

Vorige openingsprijs

70.55

Vorige sluitingsprijs

65.31

PTC Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 nov 2026, 20:26 UTC

Correlated Moves

PTC Therapeutics shares are modestly higher, supported by advances in the iShares Biotechnology ETF following positive news on Moderna's mRNA vaccine candidate.

3 nov 2026, 21:02 UTC

Social Media
News

PTC Therapeutics' Board approved a $500 million share repurchase program, reflecting confidence in growth prospects and generating positive sentiment around the stock.

2 nov 2026, 21:09 UTC

News

Citigroup reaffirms Buy rating on PTC Therapeutics and raises price target to $109, as the company prepares for upcoming investor conferences.

30 okt 2026, 20:04 UTC

Social Media
News

PTC Therapeutics reported a Q3 2026 net loss of $51.7 million and a basic EPS of -$0.62, overshadowing positive analyst ratings and price target increases.

29 okt 2026, 20:13 UTC

News

PTC Therapeutics reported a Q3 2026 net loss of $51.7 million, missing EPS estimates despite revenue of $358 million and raising full-year guidance to $1.29 to $1.32 billion.

28 okt 2026, 19:36 UTC

PTC Therapeutics, Inc. is trading higher, having reached a peak cumulative return, consistent with three consecutive daily advances.

27 okt 2026, 20:07 UTC

Correlated Moves

PTC Therapeutics is trading higher, supported by positive momentum in the biotechnology sector and gains in the SPDR S&P Biotech ETF.

23 okt 2026, 20:01 UTC

PTC Therapeutics Inc shares are declining, reversing the recent trend of higher daily closes since Thursday's close.

20 okt 2026, 20:08 UTC

Correlated Moves

PTC Therapeutics Inc is advancing, reflecting a broader positive trend in biotechnology stocks as the SPDR S&P Biotech ETF (XBI) also moves higher.

19 okt 2026, 20:01 UTC

PTC Therapeutics Inc shares are advancing despite a broader market downturn, continuing the upward momentum observed in recent sessions.

15 okt 2026, 20:02 UTC

News
Correlated Moves

UBS analyst Joon Lee raised the price target on PTC Therapeutics Inc to $90.00 from $80.00 while maintaining a Buy rating.

13 okt 2026, 20:01 UTC

PTC Therapeutics Inc shares fell sharply, continuing a decline near the low end of their one-month range and below the 20-day moving average.

9 okt 2026, 20:01 UTC

Correlated Moves

PTC Therapeutics Inc shares are advancing, recovering from an earlier dip, as the iShares Biotechnology ETF also rises, supported by strong gains in key holdings.

8 okt 2026, 20:07 UTC

Correlated Moves
News

RBC Capital maintains its Sector Perform rating on PTC Therapeutics and lowers its price target to $75, contributing to the stock's decline.

6 okt 2026, 20:07 UTC

PTC Therapeutics Inc's shares are trading roughly flat, retracing from earlier gains and remaining below the 20-day moving average amid a routine biotechnology sector performance.

28 sep 2026, 20:01 UTC

PTC Therapeutics Inc. is higher in Monday's trading session, continuing gains since Friday's close, despite an earlier pullback from a session high.

25 sep 2026, 20:01 UTC

PTC Therapeutics Inc is advancing as the broader market gains, despite earlier pulling back from a session high amid rising Treasury yields and weak consumer sentiment.

24 sep 2026, 20:07 UTC

PTC Therapeutics Inc. shares fell, closing below the 20-day moving average and near the lower end of its one-month range after midday fluctuations.

23 sep 2026, 20:02 UTC

Correlated Moves

PTC Therapeutics Inc shares fell sharply amid a broader downturn in the biotechnology sector, influenced by significant losses in the Direxion Daily S&P Biotech Bull 3X ETF.

18 sep 2026, 20:02 UTC

PTC Therapeutics Inc shares fell sharply, reversing a trend of higher daily closes seen in recent sessions, despite no specific news impacting the company.

16 sep 2026, 19:06 UTC

News

PTC Therapeutics gained after Leerink Partners initiated coverage with an "outperform" rating and a $98.00 price target, while Jefferies and Citigroup upgraded their ratings.

14 sep 2026, 20:08 UTC

News

Leerink has initiated coverage on PTC Therapeutics with an Outperform rating and a $98.00 price target, supporting a higher trading session since Friday's close.

11 sep 2026, 19:56 UTC

Social Media

PTC Therapeutics Inc shares are lower today amid discussions from an investor event and plans for a Biologics License Application for a Fabry disease treatment.

10 sep 2026, 23:41 UTC

PTC Therapeutics Inc shares are higher in after-market trading, gradually increasing since Thursday's close, despite remaining below their 20-day moving average.

8 sep 2026, 20:07 UTC

Correlated Moves

Shares lower amid decline in iShares Biotechnology ETF.

2 sep 2026, 20:08 UTC

PTC Therapeutics Inc. is gaining today, supported by a broader advance in biotechnology stocks, despite a pullback earlier in the session.

31 aug 2026, 19:46 UTC

PTC Therapeutics shares are lower today, continuing a recent decline amid broader market unease following hawkish comments from Federal Reserve Chair Kevin Warsh.

28 aug 2026, 23:36 UTC

PTC Therapeutics Inc shares are higher in after-market hours, recovering from an earlier dip. No specific news was identified to explain the movement.

27 aug 2026, 20:07 UTC

PTC Therapeutics shares are lower today, continuing a decline since Wednesday's close, despite positive labor market data. No specific news was identified.

25 aug 2026, 20:09 UTC

Event
Correlated Moves

PTC Therapeutics shares are higher as the company announces multiple data presentations for Sephience™ at an upcoming symposium in Helsinki.

Peer Vergelijking

Prijswijziging

PTC Therapeutics Inc Prognose

Koersdoel

By TipRanks

46.8% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 100 USD  46.8%

Hoogste 137 USD

Laagste 62 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor PTC Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

10

Buy

2

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
help-icon Live chat